- Home
- CGO vs COYA Comparison
CGO vs COYA Comparison
Compare CGO & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.72
Company Overview
Basic Information| Metric | CGO | COYA |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.9M | 126.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGO | COYA |
|---|---|---|
| Price | $12.32 | $4.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | 34.7K | ★ 202.9K |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,987,706.00 |
| Revenue This Year | N/A | $70.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.90 | $3.94 |
| 52 Week High | $10.93 | $8.29 |
Technical Indicators
Market Signals| Indicator | CGO | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 48.92 |
| Support Level | $12.05 | $4.41 |
| Resistance Level | $12.55 | $5.32 |
| Average True Range (ATR) | 0.16 | 0.30 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 34.52 | 46.70 |
Price Performance
Historical Comparison CGO
COYA
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.